Sanofi agrees long-awaited takeover of Genzyme
Thursday 17 February 2011
The French pharmaceuticals company Sanofi-aventis is to buy the US biotech firm Genzyme Corp in a multibillion-dollar deal it has been pursuing for nine months.
In the second largest biotech deal on record, Sanofi will pay $20.1bn (£13bn) in cash, or $74 per share, plus payments linked to the success of the US firm's drugs, including Lemtrada, Genzyme's experimental multiple sclerosis treatment.
In addition to the initial cash price, Genzyme shareholders will receive a so-called contingent value right, which will be publicly traded, mimicking an option, and which will terminate at the end of 2020 – or earlier if the specified milestones are achieved.
The CVR will give holders the right to additional payments, which could add another $3.8bn to the price tag, although the final figure depends on factors such as production levels and sales of the Genzyme drugs in question.
Sanofi's interest dates back to last year, when the French drug maker's chief executive, Christopher Viehbacher, first suggested the combination to Henri Termeer, his counterpart at Genzyme.
The record takeover comes as Sanofi attempts to bolster its revenues before a number of its patents expire. The French group said the acquisition, which is expected to close in the second quarter, would boost its underlying earnings by between €0.75 (63p) and €1 per share by 2013.
"This agreement with Genzyme is both consistent with our long-term strategy and creates significant long-term value for our shareholders," Mr Viehbacher said.
"This transaction will create a meaningful new growth platform for Sanofi-Aventis while expanding our footprint in biotechnology."
Dominic Valder, an analyst at Evolution Securities, said the acquistion meant that Sanofi's patent cliff – industry jargon for the point at which earnings inflect as big-selling drugs go off patent – had "become a patent plateau".
"The stock is now likely to have flat earnings – at approximately €7 per share for the next three years – before earnings growth starts again post 2013," he explained.
- 1 Nigel Farage: Me vs Russell Brand on Question Time – he's got the chest hair but where are his ideas?
- 2 Harry Potter fans can apply to the Hogwarts-inspired College of Wizardry
- 3 Jessica Chambers: 19-year-old woman 'doused with lighter fluid and burned alive' in the US
- 4 Russell Brand calls Nigel Farage 'poundshop Enoch Powell' in BBC Question Time debate
- 5 Orange Wednesdays are no more
Weather bomb in pictures: Storms cuts power for tens of thousands – and snow is on the way
Jessica Chambers: 19-year-old woman 'doused with lighter fluid and burned alive' in the US
Russell Brand calls Nigel Farage 'poundshop Enoch Powell' in BBC Question Time debate
Russell Brand was rendered speechless on Question Time by this man
Fury at Airbus after it hints the super-jumbo may be mothballed
Disgruntled RBS worker writes hilarious open letter to Russell Brand after anti-capitalist publicity stunt leaves him hungry
Nigel Farage defends Kerry Smith 'ch***y' comment: 'If you are going for a Chinese, what do you say you’re going for?'
Nigel Farage's approval rating hits 'record low' as popularity suffers in wake of Ukip sex scandal
Pakistan school attack live: Taliban kill at least 132 children in 'horrifying' massacre
Sony hack: Angelina Jolie branded 'seriously out of her mind' in further embarrassing leaked email saga
Panic Saturday: 13 million Britons spend £1.2bn – while 13 million others across the country live in poverty unable to afford food
iJobs Money & Business
$200 - $350 per annum: Carlton Senior Appointments: Managing Producer Office...
$125 - $225 per annum: Carlton Senior Appointments: San Fran - Investment Advi...
Up to £70,000 per annum + benefits: Sheridan Maine: Are you a qualified accoun...
Up to £65,000 per annum + benefits: Sheridan Maine: Are you a qualified accoun...